Perfluoroperhydrophenanthrene (Vitreon) in the management of giant retinal tears: results of a collaborative study.
Fifty cases of retinal detachment with a giant retinal tear were managed using perfluoroperhydrophenanthrene (Vitreon) as an intraoperative and postoperative tool. The giant tear was less than 180 degrees in 76% of the eyes, greater than 180 degrees in 22%, and greater than 270 degrees in 2%. Proliferative vitreoretinopathy was present in 40%. Vitreon was used only intraoperatively in 84% of the eyes, and was left in 16% for up to 4 weeks. Intraoperative retinal reattachment was achieved in 98%. Retinal attachment was maintained in 88%, with a mean follow up of 8.6 months. Postoperative visual acuity was better than 20/400 in 52%. Postoperative complications included cataract in 23%, choroidal effusion in 2%, hypotony in 4%, and recurrent retinal detachment with proliferative vitreoretinopathy in 26%.
Millsap
C M
CM
LSU Eye Center, Louisiana State University Medical Center School of Medicine, New Orleans.
Peyman
G A
GA
Mehta
N J
NJ
Greve
M D
MD
Lee
K J
KJ
Ma
P E
PE
Dunlap
W A
WA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005128:Eye Diseases / Q000209:etiology; D005260:Female; D005466:Fluorocarbons; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012008:Recurrence; D012163:Retinal Detachment / Q000601:surgery; D012164:Retinal Diseases / Q000209:etiology; D012167:Retinal Perforations / Q000601:surgery*; D014792:Visual Acuity; D014822:Vitreous Body
D005466:Fluorocarbons; C047722:perfluorophenanthrene